Patients with low TGF-β scores had significantly improved PFS while on immunotherapy (Fig. 3C, 8.15 months vs 2.8 months, p = 0.046), which was most noticeable in ovarian cancer despite the smaller sample size (16.6 months vs 2.65 months, p = 0.0012, Fig. 3D and Supplementary Fig. 1). Here, TGFB1 is linked to ovarian carcinoma.